{
    "nct_id": "NCT00663026",
    "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Safety, Tolerability, Reactogenicity, And Pharmacokinetic Study Of Bapineuzumab (AAB 001) Administered Subcutaneously In Subjects With Mild To Moderate AD",
    "status": "COMPLETED",
    "last_update_time": "2013-09-11",
    "description_brief": "The study will evaluate the safety and effectiveness of bapineuzumab for the treatment of mild to moderate Alzheimer disease. Subjects will be in the study for six months and will receive subcutaneous injections once per week.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "Placebo",
                    "description": "Placebo matched to bapineuzumab subcutaneous injection once weekly for 6 months."
                },
                {
                    "id": "FG001",
                    "title": "Bapineuzumab 5 mg",
                    "description": "Bapineuzumab 5 milligram (mg) subcutaneous injection once weekly for 6 months."
                },
                {
                    "id": "FG002",
                    "title": "Bapineuzumab 10 mg",
                    "description": "Bapineuzumab 10 mg subcutaneous injection once weekly for 6 months."
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "19"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "29"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "31"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "17"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "23"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "27"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "4"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Lost to Follow-up",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "Other",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "3"
                                }
                            ]
                        },
                        {
                            "type": "Caregiver Request",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "1"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Placebo",
                    "description": "Placebo matched to bapineuzumab subcutaneous injection once weekly for 6 months."
                },
                {
                    "id": "BG001",
                    "title": "Bapineuzumab 5 mg",
                    "description": "Bapineuzumab 5 milligram (mg) subcutaneous injection once weekly for 6 months."
                },
                {
                    "id": "BG002",
                    "title": "Bapineuzumab 10 mg",
                    "description": "Bapineuzumab 10 mg subcutaneous injection once weekly for 6 months."
                },
                {
                    "id": "BG003",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "19"
                        },
                        {
                            "groupId": "BG001",
                            "value": "29"
                        },
                        {
                            "groupId": "BG002",
                            "value": "31"
                        },
                        {
                            "groupId": "BG003",
                            "value": "79"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "76.16",
                                            "spread": "8.63"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "71.28",
                                            "spread": "8.73"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "72.42",
                                            "spread": "8.83"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "72.90",
                                            "spread": "8.85"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "18"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "12"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "38"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "11"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "11"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "19"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "41"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                    "description": "An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after Week 25 dose that were absent before treatment or that worsened relative to pretreatment state.",
                    "populationDescription": "Safety population included all randomized participants who received at least 1 dose of study medication.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "timeFrame": "Baseline up to 30 days after Week 25 dose",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo matched to bapineuzumab subcutaneous injection once weekly for 6 months."
                        },
                        {
                            "id": "OG001",
                            "title": "Bapineuzumab 5 mg",
                            "description": "Bapineuzumab 5 milligram (mg) subcutaneous injection once weekly for 6 months."
                        },
                        {
                            "id": "OG002",
                            "title": "Bapineuzumab 10 mg",
                            "description": "Bapineuzumab 10 mg subcutaneous injection once weekly for 6 months."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "19"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "29"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "31"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "AEs",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "16"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "22"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "28"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "SAEs",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "3"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Maximum Observed Serum Concentration (Cmax)",
                    "populationDescription": "Pharmacokinetic (PK) analysis set included all participants who provided data for the estimation of at least 1 of the relevant PK parameters (Cmax, time to maximum concentration \\[tmax\\], area under the curve \\[AUC\\], terminal elimination half-life \\[t1/2\\], apparent systemic clearance \\[CL/F\\], and apparent volume of distribution \\[Vz/F\\]).",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "nanogram per milliliter (ng/mL)",
                    "timeFrame": "Predose, 4 hours [hrs] postdose, 72 hrs postdose on Day 3 of Week 0 and 25; Predose on Day 7 (Week 1), Week 10, 14, 16, 18, 22, 26, 30; Predose and 4 hrs postdose on Week 12",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bapineuzumab 5 mg",
                            "description": "Bapineuzumab 5 milligram (mg) subcutaneous injection once weekly for 6 months."
                        },
                        {
                            "id": "OG001",
                            "title": "Bapineuzumab 10 mg",
                            "description": "Bapineuzumab 10 mg subcutaneous injection once weekly for 6 months."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "29"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "31"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "4219.97",
                                            "spread": "945.23"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "8012.88",
                                            "spread": "2793.53"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Average Serum Concentration at Steady State (Cavg,ss)",
                    "description": "Average plasma concentration at steady state (Cavg,ss) = AUCtau divided by dosing interval (1 week). AUCtau is the area under the plasma concentration time curve (AUC) at steady state from time zero (pre-dose) to end of dosing interval (tau), here dosing interval is 1 week.",
                    "populationDescription": "PK analysis set included all participants who provided data for the estimation of at least 1 of the relevant PK parameters (Cmax, tmax, AUC, t1/2, CL/F and Vz/F). Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "ng/mL",
                    "timeFrame": "Predose, 4 hrs postdose, 72 hrs postdose on Day 3 of Week 0 and 25; Predose on Day 7 (Week 1), Week 10, 14, 16, 18, 22, 26, 30; Predose and 4 hrs postdose on Week 12",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bapineuzumab 5 mg",
                            "description": "Bapineuzumab 5 milligram (mg) subcutaneous injection once weekly for 6 months."
                        },
                        {
                            "id": "OG001",
                            "title": "Bapineuzumab 10 mg",
                            "description": "Bapineuzumab 10 mg subcutaneous injection once weekly for 6 months."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "25"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "29"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "3123.071",
                                            "spread": "1074.116"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "6912.301",
                                            "spread": "2149.143"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Serum Decay Half-Life (t1/2)",
                    "description": "Serum decay half-life is the time measured for the serum concentration to decrease by one half.",
                    "populationDescription": "t1/2 not calculated due to inadequate characterization of the terminal elimination phase.",
                    "reportingStatus": "POSTED",
                    "timeFrame": "Predose, 4 hrs postdose, 72 hrs postdose on Day 3 of Week 0 and 25; Predose on Day 7 (Week 1), Week 10, 14, 16, 18, 22, 26, 30; Predose and 4 hrs postdose on Week 12",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bapineuzumab 5 mg",
                            "description": "Bapineuzumab 5 milligram (mg) subcutaneous injection once weekly for 6 months."
                        },
                        {
                            "id": "OG001",
                            "title": "Bapineuzumab 10 mg",
                            "description": "Bapineuzumab 10 mg subcutaneous injection once weekly for 6 months."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "0"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "0"
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Time to Reach Maximum Observed Serum Concentration (Tmax)",
                    "populationDescription": "PK analysis set included all participants who provided data for the estimation of at least 1 of the relevant PK parameters (Cmax, tmax, AUC, t1/2, CL/F and Vz/F).",
                    "reportingStatus": "POSTED",
                    "paramType": "MEDIAN",
                    "dispersionType": "Full Range",
                    "unitOfMeasure": "hours",
                    "timeFrame": "Predose, 4 hrs postdose, 72 hrs postdose on Day 3 of Week 0 and 25; Predose on Day 7 (Week 1), Week 10, 14, 16, 18, 22, 26, 30; Predose and 4 hrs postdose on Week 12",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bapineuzumab 5 mg",
                            "description": "Bapineuzumab 5 milligram (mg) subcutaneous injection once weekly for 6 months."
                        },
                        {
                            "id": "OG001",
                            "title": "Bapineuzumab 10 mg",
                            "description": "Bapineuzumab 10 mg subcutaneous injection once weekly for 6 months."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "29"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "31"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "3696.00",
                                            "lowerLimit": "1680.00",
                                            "upperLimit": "4368.00"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "4200.00",
                                            "lowerLimit": "72.00",
                                            "upperLimit": "4368.00"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)",
                    "description": "AUCtau is the area under the serum concentration time curve (AUC) at steady state from time zero (pre-dose) to end of dosing interval (tau), here dosing interval is 1 week.",
                    "populationDescription": "PK analysis set included all participants who provided data for the estimation of at least 1 of the relevant PK parameters (Cmax, tmax, AUC, t1/2, CL/F and Vz/F). Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "ng*hr/mL",
                    "timeFrame": "Predose, 4 hrs postdose, 72 hrs postdose on Day 3 of Week 0 and 25; Predose on Day 7 (Week 1), Week 10, 14, 16, 18, 22, 26, 30; Predose and 4 hrs postdose on Week 12",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bapineuzumab 5 mg",
                            "description": "Bapineuzumab 5 milligram (mg) subcutaneous injection once weekly for 6 months."
                        },
                        {
                            "id": "OG001",
                            "title": "Bapineuzumab 10 mg",
                            "description": "Bapineuzumab 10 mg subcutaneous injection once weekly for 6 months."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "25"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "31"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "524675.88",
                                            "spread": "180451.56"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1161266.63",
                                            "spread": "361056.04"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Apparent Systemic Clearance (CL/F)",
                    "description": "Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after subcutaneous dose (apparent systemic clearance) is influenced by the fraction (F) of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Steady-state apparent systemic clearance (CL/F) was calculated as dose/AUC tau.",
                    "populationDescription": "PK analysis set included all participants who provided data for the estimation of at least 1 of the relevant PK parameters (Cmax, tmax, AUC, t1/2, CL/F and Vz/F). Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "milliliter/hour/kilogram (mL/hr/kg)",
                    "timeFrame": "Predose, 4 hrs postdose, 72 hrs postdose on Day 3 of Week 0 and 25; Predose on Day 7 (Week 1), Week 10, 14, 16, 18, 22, 26, 30; Predose and 4 hrs postdose on Week 12",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Bapineuzumab 5 mg",
                            "description": "Bapineuzumab 5 milligram (mg) subcutaneous injection once weekly for 6 months."
                        },
                        {
                            "id": "OG001",
                            "title": "Bapineuzumab 10 mg",
                            "description": "Bapineuzumab 10 mg subcutaneous injection once weekly for 6 months."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "25"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "29"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.16",
                                            "spread": "0.05"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.132",
                                            "spread": "0.069"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "description": "The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Placebo",
                    "description": "Placebo matched to bapineuzumab subcutaneous injection once weekly for 6 months.",
                    "seriousNumAffected": 1,
                    "seriousNumAtRisk": 19,
                    "otherNumAffected": 15,
                    "otherNumAtRisk": 19
                },
                {
                    "id": "EG001",
                    "title": "Bapineuzumab 5 mg",
                    "description": "Bapineuzumab 5 milligram (mg) subcutaneous injection once weekly for 6 months.",
                    "seriousNumAffected": 2,
                    "seriousNumAtRisk": 29,
                    "otherNumAffected": 22,
                    "otherNumAtRisk": 29
                },
                {
                    "id": "EG002",
                    "title": "Bapineuzumab 10 mg",
                    "description": "Bapineuzumab 10 mg subcutaneous injection once weekly for 6 months.",
                    "seriousNumAffected": 3,
                    "seriousNumAtRisk": 31,
                    "otherNumAffected": 27,
                    "otherNumAtRisk": 31
                }
            ],
            "seriousEvents": [
                {
                    "term": "Atrial fibrillation",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Serum sickness",
                    "organSystem": "Immune system disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Lobar pneumonia",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Subdural hemorrhage",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Convulsion",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Subarachnoid hemorrhage",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Delirium",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Cystocele",
                    "organSystem": "Reproductive system and breast disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Rectocele",
                    "organSystem": "Reproductive system and breast disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 31
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Tympanic membrane perforation",
                    "organSystem": "Ear and labyrinth disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Diarrhoea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 5,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 2,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Dyspepsia",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Gastric haemorrhage",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Hiatus hernia",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Nausea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 2,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Rectal haemorrhage",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 2,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Fatigue",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Injection site erythema",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Injection site haemorrhage",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Injection site pain",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Vessel puncture site haematoma",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Seasonal allergy",
                    "organSystem": "Immune system disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Nasopharyngitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Rhinitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 2,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Sinusitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Upper respiratory tract infection",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 6,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Urinary tract infection",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Arthropod bite",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Contusion",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 3,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 2,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 2,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Tendon rupture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Blood cholesterol increased",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Weight decreased",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Arthralgia",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Back pain",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Myalgia",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Neck pain",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Osteoarthritis",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Polyarthritis",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Atypical fibroxanthoma",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 2,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Headache",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 2,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Paraesthesia",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Somnolence",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Vasogenic cerebral oedema",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 6,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Agitation",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Anxiety",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Depression",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Hallucination",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Insomnia",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Cough",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Epistaxis",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Rhinitis allergic",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 2,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Psoriasis",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Rash",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Rash papular",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 31
                        }
                    ]
                },
                {
                    "term": "Orthostatic hypotension",
                    "organSystem": "Vascular disorders",
                    "sourceVocabulary": "MedDRA v13.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 29
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 31
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "limitationsAndCaveats": {
                "description": "Designation of outcomes as primary, secondary was based on study team's input as study did not specify them as primary or secondary."
            },
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true,
                "otherDetails": "Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."
            },
            "pointOfContact": {
                "title": "Pfizer ClinicalTrials.gov Call Center",
                "organization": "Pfizer, Inc.",
                "email": "ClinicalTrials.gov_Inquiries@pfizer.com",
                "phone": "1-800-718-1021"
            }
        }
    },
    "target_category": "disease-targeted biologic",
    "drug": [
        "bapineuzumab (AAB-001) \u2014 humanized monoclonal antibody against amyloid-\u03b2"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The investigational product is bapineuzumab (AAB-001), a humanized monoclonal antibody that binds amyloid-\u03b2 and was developed to clear or neutralize amyloid pathology\u2014i.e., a biologic intended to target Alzheimer disease pathology (disease modification). \ue200cite\ue202turn0search6\ue202turn0search0\ue201",
        "Act: Key trial details extracted from the description \u2014 drug: bapineuzumab (AAB-001); population: mild-to-moderate AD; design: randomized, double-blind, placebo-controlled, multiple ascending dose safety/tolerability PK study; route/frequency in this protocol: subcutaneous injections once weekly. Note: most large bapineuzumab trials used intravenous dosing every 13 weeks, but the compound is consistently described in the literature as a humanized anti\u2013amyloid-\u03b2 monoclonal antibody. \ue200cite\ue202turn0search6\ue202turn0search7\ue201",
        "Web-search supporting results (selected): phase\u20111/phase\u20112 publications describe bapineuzumab as a humanized anti\u2013amyloid-\u03b2 monoclonal antibody (AAB\u2011001) studied in mild\u2011to\u2011moderate AD. \ue200cite\ue202turn0search0\ue202turn0search6\ue201",
        "Web-search supporting results (selected): Phase\u20113 trials showed no clinical benefit on primary cognitive endpoints and identified amyloid\u2011related imaging abnormalities (ARIA) as a notable safety concern at higher doses. These publications confirm the drug's mechanism (amyloid targeting) and its classification as a biologic. \ue200cite\ue202turn0search7\ue202turn0search2\ue201",
        "Reflect: Classification check \u2014 bapineuzumab is not a small molecule, not a symptomatic cognitive enhancer, and not aimed at neuropsychiatric symptom relief; it is an anti\u2013amyloid biologic designed to target Alzheimer pathology. Therefore the correct category is 'disease-targeted biologic'. \ue200cite\ue202turn0search6\ue202turn0search7\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: The investigational product is bapineuzumab (AAB-001), a humanized monoclonal antibody that binds amyloid-\u03b2 and was developed to clear or neutralize amyloid pathology (i.e., it directly targets amyloid-\u03b2). \ue200cite\ue202turn0search0\ue202turn0search7\ue201",
        "Act: Extracted details \u2014 drug: bapineuzumab (AAB\u2011001); mechanism: anti\u2013amyloid-\u03b2 monoclonal antibody; population: mild-to-moderate AD; study type: randomized, double\u2011blind, placebo\u2011controlled, multiple ascending dose safety/tolerability/PK; note on dosing: many published bapineuzumab trials used IV dosing every ~13 weeks and reported a half\u2011life supporting that interval, though the protocol you provided specifies subcutaneous weekly administration. \ue200cite\ue202turn0search0\ue202turn0search6\ue201",
        "Reflect: Bapineuzumab\u2019s mechanism is explicitly amyloid\u2011targeting and is not primarily symptomatic, multi-target, or a non\u2011therapeutic diagnostic \u2014 therefore the correct CADRO classification is A) Amyloid beta. This is consistent with phase\u20112/3 program findings (biomarker effects on amyloid but no clinical benefit and occurrence of amyloid\u2011related imaging abnormalities). \ue200cite\ue202turn0search6\ue202turn0search1\ue201",
        "Web-search supporting results (selected): 1) Phase\u20111 single ascending dose study describes bapineuzumab as a humanized monoclonal antibody to amyloid\u2011\u03b2 and gives PK/half\u2011life data supporting 13\u2011week dosing. \ue200cite\ue202turn0search0\ue201 2) Two global phase\u20113 trials in mild\u2011to\u2011moderate AD reported no clinical benefit on primary endpoints; ARIA was the major safety signal. \ue200cite\ue202turn0search6\ue202turn0search4\ue201 3) Centralized/pooled analyses document the incidence and characteristics of amyloid\u2011related imaging abnormalities (ARIA\u2011E/ARIA\u2011H) in bapineuzumab trials. \ue200cite\ue202turn0search1\ue202turn0search5\ue201"
    ]
}